Video Experimental Relacionado
Updated: Jul 19, 2026
08:35
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Los inhibidores orales de la renina
Jan A Staessen1, Yan Li, Tom Richart
1Studies Coordinating Centre, Division of Hypertension and Cardiovascular Rehabilitation, Department of Cardiovascular Diseases, University of Leuven, Leuven, Belgium. jan.staessen@med.kuleuven.be
Lancet (London, England)
|October 24, 2006
Resumen
Los inhibidores de la renina bloquean el sistema renina-angiotensina para tratar trastornos cardiovasculares y renales. Aliskiren, un nuevo inhibidor de la renina oral, es prometedor para la hipertensión y condiciones relacionadas.
Área de la Ciencia:
- Farmacología Farmacología.
- Medicina Cardiovascular La medicina cardiovascular es una especialidad de la salud.
- Nefrología Nefrología.
Sus antecedentes:
- El sistema renina-angiotensina juega un papel clave en los trastornos cardiovasculares y renales.
- La inhibición de la renina, el origen del sistema, ha sido un objetivo terapéutico durante más de 30 años.
- Los inhibidores orales anteriores de la renina carecían de eficacia clínica debido a su escasa biodisponibilidad y actividad.
Objetivo del estudio:
- Revisar el desarrollo de inhibidores orales de la renina.
- Para resumir las propiedades farmacocinéticas y farmacodinámicas de estos agentes.
- Para centrarse en aliskiren, el primer inhibidor de la renina no peptídico en ensayos de fase III.
Principales métodos:
- Revisión de los datos preclínicos y clínicos sobre los inhibidores orales de la renina.
- Análisis de los perfiles farmacocinéticos y farmacodinámicos.
- Centrarse en la progresión de aliskiren en los ensayos clínicos.
Principales resultados:
- Aliskiren es el primer inhibidor de la renina no peptídico activo por vía oral en alcanzar los ensayos clínicos de fase III.
- Demuestra potencial para el tratamiento de la hipertensión y los trastornos cardiovasculares y renales asociados.
- Nuevos compuestos con propiedades mejoradas están bajo investigación preclínica.
Conclusiones:
- Los inhibidores orales de la renina representan un avance significativo en el manejo de enfermedades mediadas por el sistema renina-angiotensina.
- Aliskiren es un candidato líder para uso clínico en hipertensión y afecciones relacionadas.
- La investigación en curso tiene como objetivo desarrollar mejores inhibidores orales de la renina con mejor biodisponibilidad y eficacia.
Videos de Conceptos Relacionados
01:25Antihypertensive Drugs: Direct Renin Inhibitors
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
01:33Hormonal Regulation
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
01:30Continuous Renal Replacement Therapy
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...